OS Cancer Research Results

OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
5361- almon,    Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
- Trial, NSCLC, NA
EGFR↓, OS↑, Dose↝,
5360- almon,  BEV,    Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
- Case Report, NSCLC, NA
BBB↑, Dose↝, eff↓, OS↑,
5357- almon,    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
- Trial, NSCLC, NA
EGFR↓, eff↝, OS↑,
5623- Bif,    Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
- Study, NSCLC, NA
GutMicro↑, OS↑, eff↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
224- MFrot,  MF,    A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms
- Human, NSCLC, NA
PleEff↓, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, OS↑,
5285- Ramu,  docx,    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
- Trial, NSCLC, NA
OS↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

OXPHOS↑, 1,   ROS↑, 2,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics ⓘ

PleEff↓, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PDKs↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

BowelM↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

LC3s↓, 1,   p62↑, 1,   TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 1,   mTOR↓, 1,   TumCG↓, 2,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 2,   eff↓, 1,   eff↑, 4,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   Ferritin↓, 1,   GutMicro↑, 1,  

Functional Outcomes ⓘ

Appetite↑, 1,   breath↑, 1,   OS↑, 7,   Pain↓, 1,   Strength↑, 1,   toxicity↝, 1,  
Total Targets: 38

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: OS, overall survival
3 almonertinib
1 Bevacizumab (brand Avastin)
1 Bifidobacterium
1 Dichloroacetate
1 salinomycin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Ramucirumab (CYRAMZA)
1 Docetaxel
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:229  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page